Table 2 Treatment line characteristics (n = 871), grouped by no ST (None), mild ST, and severe ST
None | Mild | Severe | P | |
|---|---|---|---|---|
n (%) | 617 (70.8) | 191 (22.0) | 63 (7.2) | |
Cancer (%) | ||||
Melanoma | 257 (41.7) | 86 (45.0) | 44 (69.8) | <0.001 |
Brain | 20 (3.2) | 3 (1.6) | 1 (1.6) | |
Breast | 31 (5.0) | 7 (3.7) | 0 (0.0) | |
Genitourinary | 17 (2.8) | 9 (4.7) | 0 (0.0) | |
Head and neck | 25 (4.1) | 4 (2.1) | 0 (0.0) | |
Kidney | 26 (4.2) | 15 (7.9) | 6 (9.5) | |
Liver and intrahepatic bile ducts | 25 (4.1) | 7 (3.7) | 2 (3.2) | |
Lung | 131 (21.2) | 47 (24.6) | 6 (9.5) | |
Mesothelial and soft tissue | 26 (4.2) | 0 (0.0) | 0 (0.0) | |
Ovarian and fallopian tube | 13 (2.1) | 5 (2.6) | 1 (1.6) | |
Pancreatic | 8 (1.3) | 1 (0.5) | 1 (1.6) | |
Non-melanoma skin | 23 (3.7) | 0 (0.0) | 0 (0.0) | |
Stomach | 9 (1.5) | 4 (2.1) | 1 (1.6) | |
Uterine | 6 (1.0) | 3 (1.6) | 1 (1.6) | |
ICI treatment category (%) | 0.017 | |||
Anti-CTLA-4 | 63 (10.2) | 23 (12.0) | 17 (27.0) | |
Anti-CTLA-4 + Anti-PD-1 | 123 (19.9) | 39 (20.4) | 14 (22.2) | |
Anti-PD-1 | 402 (65.2) | 122 (63.9) | 31 (49.2) | |
Anti-PD-L1 | 25 (4.1) | 7 (3.7) | 1 (1.6) | |
Other | 4 (0.6) | 0 (0.0) | 0 (0.0) | |
Adjuvant vs metastatic (%) | 0.301 | |||
Adjuvant | 44 (7.1) | 21 (11.0) | 8 (12.7) | |
Metastatic | 572 (92.7) | 171 (89.0) | 55 (87.3) | |
Neo-adjuvant | 1 (0.2) | 0 (0.0) | 0 (0.0) | |
Response to treatment (%) | <0.001 | |||
Complete response | 68 (11.4) | 41 (21.7) | 8 (13.1) | |
Partial response | 104 (17.4) | 57 (30.2) | 17 (27.9) | |
Stable disease | 99 (16.5) | 37 (19.6) | 13 (21.3) | |
Progression of disease | 328 (54.8) | 54 (28.6) | 23 (37.7) | |
Hospitalization due to toxicity = Yes (%) | 57 (9.2) | 13 (6.8) | 4 (6.3) | 0.469 |
Discontinued due to toxicity = Yes (%) | 87 (14.1) | 21 (11.0) | 18 (28.6) | 0.002 |
Discontinued due to progression of disease = Yes (%) | 409 (66.3) | 84 (44.0) | 29 (46.0) | <0.001 |